Our HTGF Portfolio of startups offers excellent opportunities and is always hiring talented people.
Incephalo develops exclusively local treatments for neurological diseases, with a focus on cancers in the brain (primary brain cancers as well as secondary brain cancers). The proprietary compartment lock technology, also called C-LOCK, retains biologics that are applied locally behind the blood-brain barrier, in the central nervous system (CNS), and once they leave the CNS, degrades them rapidly in the systemic compartment. Thereby, it significantly improves local CNS therapy, a challenging task with regards to achieving high local concentration (for efficacy) and low systemic footprint (to reduce potential side effects). Especially, the peripheral side effects still limit various promising candidates for the treatment of brain cancer or other neurological diseases.
Something looks off?